Hank Greely, Jake Sherkow, and Matt Lamkin discuss fMRI lie-detection services, pay-to-delay settlements between branded pharmaceutical and generics companies, and the arguments against increased regulation of enhancement technologies.

Hank Greely, Patti Zettler, Dmitry Karshtedt, and Stephanie Bair discuss new developments related to the Biosimilars Act and FDA's orphan drug program, the policy implications of brain myths, and the current Ebola crisis.